A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Relpax Overdose, Contraindications and Information - Eletriptan hydrobromide
Relpax Overdose, Contraindications and Information - Eletriptan hydrobromide
OVERDOSE
No significant overdoses in premarketing clinical trials have
been reported. Volunteers (N=21) have received single doses of 120 mg without
significant adverse effects. Daily doses of 160 mg were commonly employed in
Phase III trials. Based on the pharmacology of the 5-HT1B/1D agonists,
hypertension or other more serious cardiovascular symptoms could occur on overdose.
The elimination half-life of eletriptan is about 4 hours (see CLINICAL
PHARMACOLOGY) and therefore monitoring of patients after overdose with
eletriptan should continue for at least 20 hours, or longer should symptoms
or signs persist. There is no specific antidote to eletriptan. In cases of severe
intoxication, intensive care procedures are recommended, including establishing
and maintaining a patent airway, ensuring adequate oxygenation and ventilation,
and monitoring and support of the cardiovascular system. It is unknown what
effect hemodialysis or peritoneal dialysis has on the serum concentration of
eletriptan.
CONTRAINDICATIONS
RELPAX Tablets should not be given to patients with ischemic
heart disease (e.g., angina pectoris, history of myocardial infarction, or documented
silent ischemia) or to patients who have symptoms, or findings consistent with
ischemic heart disease, coronary artery vasospasm, including Prinzmetal’s variant
angina, or other significant underlying cardiovascular disease (see WARNINGS).
RELPAX Tablets should not be given to patients with cerebrovascular syndromes
including (but not limited to) strokes of any type as well as transient ischemic
attacks (see WARNINGS). RELPAX Tablets should
not be given to patients with peripheral vascular disease including (but not
limited to) ischemic bowel disease (see WARNINGS).
Because RELPAX Tablets may increase blood pressure, it should not be given to
patients with uncontrolled hypertension (see WARNINGS).
RELPAX Tablets should not be administered to patients with hemiplegic or basilar
migraine. RELPAX Tablets should not be used within 24 hours of treatment with
another 5-HT1 agonist, an ergotamine-containing or ergot-type medication
such as dihydroergotamine (DHE) or methysergide. RELPAX Tablets should not be
used in patients with known hypersensitivity to eletriptan or any of its inactive
ingredients. RELPAX Tablets should not be given to patients with severe hepatic
impairment.
top
